Analytical Study of the Middle East Veterinary Vaccine Industry (2023 to 2033)
The Middle East veterinary vaccine industry size is projected to expand at a 4% CAGR through 2033. The demand outlook for veterinary vaccines in the Middle East is US$ 627.1 million in 2023. By 2033, sales of veterinary vaccines in the Middle East are anticipated to cross a valuation of US$ 973.8 million.
Attributes
Details
Middle East Veterinary Vaccine Industry Size in 2023
US$ 627.1 million
Expected Industry Size by 2033
US$ 973.8 million
Value-based CAGR from 2023 to 2033
4%
Key Trends Influencing Demand through 2033
The Middle East is investing significant resources in biotechnology and research, supporting innovation in veterinary vaccine manufacturing. This investment strengthens the industry's capabilities and raises the region's profile in the global biotech industry.
Significant zoonotic disease outbreaks, such as MERS, have occurred in the region. Recognizing the significant health and economic ramifications, the Middle East prioritizes animal immunization to protect both animal and human health.
The Middle East has a thriving livestock industry that caters to the expanding demand for meat, dairy, and poultry products. Veterinary vaccinations are critical for minimizing illness risks and guaranteeing these animals' health and production.
The region quickly embraces digital technologies and data-driven solutions for disease tracking, animal health surveillance, and optimizing vaccine distribution. This digital shift improves efficiency and effectiveness across the veterinary vaccine value chain.
The Middle East has a large population of camels, which play a substantial role in the region's culture and commerce. As a result, there is a unique tendency toward creating camel-specific vaccines to serve the camel farming and racing businesses.
Advanced data analytics and predictive modeling are being used to forecast illness outbreaks, enabling preventive immunization efforts and reducing the region's economic burden from diseases.
To increase animal health and alleviate poverty, certain Middle Eastern governments are working to ensure equitable access to veterinary vaccines for underprivileged and nomadic people, particularly in distant places.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
Key Insights on Emerging Opportunities in the Middle East Veterinary Vaccine Industry
Companies can create hydroponic feed solutions and additives that are designed to improve animal health and vaccination success. This meets the growing demand for new solutions in the agriculture industry.
Businesses can tackle logistical problems and ensure a consistent vaccine supply by creating vaccine banks and cold storage facilities. This is especially advantageous for rural and underserved areas, as it reduces supply chain disturbances.
As livestock farming becomes more popular in the Middle East, insurance firms should embrace the chance to offer livestock insurance, including coverage against illnesses and vaccination-related losses, expanding their portfolio and meeting the demands of livestock owners.
Developing training institutes dedicated to training veterinarians and animal health professionals is a lucrative business. These facilities cater to the workforce's training needs by offering vaccine delivery, disease control, and biosecurity procedure courses.
Middle Eastern collaborations with global vaccine makers can result in knowledge transfer and license agreements. This association promotes the exchange of information and technology, which can lead to localized vaccine manufacturing and export prospects
Historical Performance of the Middle East Veterinary Vaccine Industry
Attributes
Details
Middle East Veterinary Vaccine Industry Size (2018)
US$ 510.8 million
Middle East Veterinary Vaccine Industry Size (2022)
US$ 627.1 million
The Middle East's livestock and agriculture industries have grown significantly in recent years due to rising demand for meat, dairy, and other animal-based products. This developing industry requires the use of veterinary vaccinations to ensure the health and productivity of animals, consequently stimulating the veterinary vaccine sector's growth. Biosecurity and disease management have become critical in the livestock and agriculture industries of the Middle East. Robust procedures, including vaccination, are required to prevent disease spread within and across animal populations, fueling industry growth.
Businesses in the Middle East veterinary vaccine industry are vying to minimize the environmental effect of vaccine manufacturing and distribution as sustainability goals gain importance in the Middle East. Green practices and eco-friendly solutions are in line with the region's environmental goals. Animal disease outbreaks can have significant economic and public health consequences in the Middle East. By guaranteeing animal health through vaccination, the region mitigates these dangers while protecting the food supply and public health interests.
In the coming years, the global demand for animal-based protein is predicted to rise further as the world's population grows with rising incomes. This will increase the demand for efficient disease prevention methods such as veterinary vaccinations. Biotechnology, genetics, and immunology advancements result in the development of more accurate, efficacious, and novel veterinary vaccines. These innovations improve the industry's capacity to tackle new and emerging illnesses. Recognizing the interconnection of human, animal, and environmental health, the One Health concept is expected to foster collaboration between the veterinary and human health sectors for disease management initiatives.
Find your sweet spots for generating winning opportunities in this market.
Comparative View of the Adjacent Middle East Veterinary Vaccine Industry
Two industries related to the Veterinary Vaccine and Veterinary Hospital industries. As per the analysis, the rising pet adoption is anticipated to fuel expansion across the mentioned industries. The rising advancements in animal health monitoring and disease surveillance are expected to boost revenues across these industries. The ongoing developments in vaccine production are expected to influence growth across these industries. The rising awareness for animal welfare will also gain prominence and create opportunities across these industries in the coming years.
Middle East Veterinary Vaccine Industry:
Attributes
Middle East Veterinary Vaccine Industry
CAGR (2023 to 2033)
4%
Market Value (2023)
US$ 627.1 million
Growth Factors
Increasing investment in aquaculture Rising focus on livestock health
Future Opportunities
Development of halal-certified veterinary vaccines
Market Trends
Advancements in disease forecasting and monitoring solutions
Veterinary Vaccine Industry:
Attributes
Veterinary Vaccine Industry
CAGR (2023 to 2033)
6.2%
Market Value (2023)
US$ 11.3 billion
Growth Factors
Increasing expenditure on pet care Rising adoption of efficient immunizations
Future Opportunities
Increased government investments
Market Trends
Rising advancements in vaccine development
Veterinary Hospital Industry:
Attributes
Veterinary Hospital Industry
CAGR (2023 to 2033)
6.2%
Market Value (2023)
US$ 79.54 billion
Growth Factors
Continued modernization of advanced veterinary healthcare infrastructure. Increasing pet adoption globally.
Future Opportunities
Increased veterinary healthcare expenditure.
Market Trends
Growing awareness for animal welfare.
Category-wise Insights
Rising Investments to Boost Local Manufacturing Fuel Demand for Attenuated Live Vaccines
Leading Vaccine Technology in the Middle East
Attenuated Live Vaccines Technology
Total Value Share (2023)
34.20%
The Middle East's surging investments in biotechnology and research are boosting the domestic production of attenuated live vaccines. This coincides with the region's objective of vaccine self-sufficiency and enables customization to meet particular area disease issues. Live attenuated vaccines have proven to be useful in preventing a variety of animal illnesses. They provide a cost-effective disease management option, which is especially tempting in the Middle East's livestock and agriculture industries, where economic concerns are essential.
Government-led Initiatives Promote Livestock Sector’s Growth in the Middle East
Leading Animal Type in the Middle East
Livestock Animals
Total Value Share (2023)
74.40%
Governments around the Middle East are fiercely encouraging the expansion of the livestock sector, with many of their activities involving disease control through vaccination campaigns. The Middle East is home to a diversified animal population, which includes cattle, sheep, goats, and even camels. Each species has unique disease problems, requiring a range of vaccinations carefully tailored to each animal type's needs. Several Middle Eastern nations are making huge investments in agriculture and animal husbandry to improve food security. As the livestock industry grows, the demand for veterinary vaccinations to protect animal health and production aligns with national food security goals.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need and save 40%!
Country-wise Insights
Countries
Value-based CAGR (2023 to 2033)
KSA
4.9%
UAE
5.1%
Iran
4.3%
Israel
4.0%
Egypt
5.3%
KSA’s Vision 2030 Initiatives Boost Investments in Veterinary Vaccine Industry
Sales of veterinary vaccines in the Kingdom of Saudi Arabia (KSA) are expected to rise at a 4.9% CAGR through 2033. The Kingdom of Saudi Arabia's Vision 2030 strategic efforts focus on non-oil industries such as agriculture and healthcare. This commitment drives investments in the veterinary vaccine business, aligning with the country's economic diversification objectives. Royal support for agriculture, particularly animal husbandry, leads to greater financing and incentives for veterinary vaccine research and manufacturing. This royal encouragement has created a favorable atmosphere for the growth of the veterinary vaccine sector.
Rising Focus on Genetic Improvements Gain Prominence in the UAE
The UAE veterinary vaccines industry is projected to expand at a 5.1% CAGR through 2033. The UAE's emphasis on genetic development in livestock breeds to increase performance has increased the demand for vaccinations that protect genetically superior animals. As a result, customized vaccinations that target these breeds' specific health needs are gaining popularity. The UAE's efforts in state-of-the-art research and development, including genomics and biotechnology, have sparked the development of novel vaccinations suited to the particular animal health issues in the area. These developments are attracting both domestic and international stakeholders.
Iran’s Geostrategic Location Provides a Gateway for Trade
Sales of veterinary vaccines in Iran are expected to rise at a 4.3% CAGR through 2033. Iran has been subjected to international sanctions, driving self-sufficiency measures in a variety of industries, including healthcare. These self-sufficiency programs have supported the veterinary vaccine sector, leading to greater domestic manufacturing and an emphasis on innovation. The strategic location of Iran serves as a gateway for trade for Asia, Europe, and the Middle East. As trade networks increase, there is a greater demand for livestock vaccination to fulfill international animal health standards and enable commerce, hence promoting the expansion of the veterinary vaccine industry.
Geopolitical Tensions Largely Impact Industry Expansion in Israel
The demand for veterinary vaccines in Israel is likely to increase at a 4.0% CAGR through 2033. However, in light of recent geopolitical tensions between Israel and its neighboring countries, revenues of several industries are expected to be affected. Despite this, the Israeli government's significant emphasis on national security extends to biosecurity issues. The veterinary vaccine sector is vital in preserving cattle and animal populations, guaranteeing food security, and preventing bioterrorism.
Increasing Focus on Food Security Drives Investments in Egypt
The veterinary vaccine industry in Egypt is anticipated to accelerate at a 5.3% CAGR through 2033. The Egyptian government's emphasis on food security and self-sufficiency encourages investments in the livestock sector and the veterinary vaccination business. The industry is critical to ensuring the health and well-being of cattle, therefore contributing to the nation's food security goals. Egypt's participation in Pan-African agricultural projects and collaborations has resulted in a rising need for vaccinations that are compliant with regional disease control and trade standards, establishing the country as a prominent participant in African agriculture.
Competitive Landscape in the Middle East Veterinary Vaccine Industry
The Middle East veterinary vaccines industry's competitive environment is defined by a broad array of players and entities, each of which contributes to the sector's growth and development. Multinational pharmaceutical conglomerates like Zoetis, MSD Animal Health (Merck Animal Health in the United States and Canada), and Boehringer Ingelheim have a prominent presence in the region. These firms provide a wide range of vaccines, building on established brand awareness using their global reach and substantial research capabilities. Key players provide complete solutions to a wide range of animal health issues across the Middle East.
Recent Developments in the Middle East Veterinary Vaccine Industry
Bill Gates, Co-chair of the Bill & Melinda Gates Foundation, announced new investments at the 2023 Grand Challenges Annual Meeting in October 2023 to advance access to mRNA research and vaccine manufacturing technology. This will support low- and middle-income countries' (LMICs') capacity to develop large-scale, high-quality, lifesaving vaccines. The decision builds on the foundation's more than 20 years of experience working with vaccine producers in LMICs, as well as the chance to use recent scientific discoveries to develop low-cost, high-quality health tools that reach more people throughout the world.
Kansas State University's College of Veterinary Medicine announced the establishment of the new Center on Vaccine Evaluation and Alternatives for Antimicrobials, or CVEAA, in July 2023 to promote animal vaccine development and use.
Key Players in the Middle East Veterinary Vaccine Industry
JOVAC
Bioveta, Inc.
Intervac Pvt. Ltd.
Zoetis
Elanco
Merial
Merck & Co. Inc.
Bayer Pharma AG
Ceva
Boehringer Ingelheim
MSD Animal Health
Middle East Veterinary Vaccine Industry Segmentation
By Vaccine:
Attenuated Live Vaccines
Inactivated Vaccines
Toxoid Vaccines
DNA Vaccines
Recombinant Vaccines
Others
By Animal:
Companion Animals
Canine
Avian
Feline
Livestock Animals
Aquatic
Bovine
Porcine
Small Ruminant
Poultry
Equine
By Disease Indication:
Foot and Mouth Disease
Newcastle Disease
PPRS
Canine Parvovirus
Brucellosis
Avian Influenza
Others
By End User:
Hospital Pharmacies
Veterinary Clinics
Private Veterinary Pharmacies
Others
By Country:
UAE
KSA
Turkey
Jordan
Sudan
Egypt
Rest of MEA
Frequently Asked Questions
How Big is the Middle East Veterinary Vaccines Industry?
The Middle East veterinary vaccine market size is US$ 627.1 million in 2023.
What is the Projected CAGR of the Middle East Veterinary Vaccines Industry?
The Middle East veterinary vaccine market is expected to rise at a 4% CAGR through 2033.
What is the Middle East Veterinary Vaccine Industry Outlook?
The Middle East veterinary vaccine market size will be worth US$ 973.8 million by 2033.
What is the Preferred Vaccine Technology in the Middle East Veterinary Vaccine Industry?
The demand for attenuated live vaccine technology is high in the industry.
Which Country is Leading the Middle East Veterinary Vaccines Industry Growth?
The Middle East veterinary vaccine market size in Egypt is expected to rise at a 5.3% CAGR through 2033.
Table of Content
1. Executive Summary
1.1. Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
3.3. Opportunity Map Analysis
3.4. Product Life Cycle Analysis
3.5. Supply Chain Analysis
3.5.1. Supply Side Participants and their Roles
3.5.1.1. Producers
3.5.1.2. Mid-Level Participants (Traders/ Agents/ Brokers)
3.5.1.3. Wholesalers and Distributors
3.5.2. Value Added and Value Created at Node in the Supply Chain
3.5.3. List of Raw Material Suppliers
3.5.4. List of Existing and Potential Buyer’s
3.6. Investment Feasibility Matrix
3.7. Value Chain Analysis
3.7.1. Profit Margin Analysis
3.7.2. Wholesalers and Distributors
3.7.3. Retailers
3.8. PESTLE and Porter’s Analysis
3.9. Regulatory Landscape
3.9.1. By Key Regions
3.9.2. By Key Countries
3.10. Regional Parent Market Outlook
3.11. Production and Consumption Statistics
3.12. Import and Export Statistics
4. Market Analysis 2018 to 2022 and Forecast, 2023 to 2033
4.1. Historical Market Size Value (US$ Million) & Volume (Units) Analysis, 2018 to 2022
4.2. Current and Future Market Size Value (US$ Million) & Volume (Units) Projections, 2023 to 2033
4.2.1. Y-o-Y Growth Trend Analysis
4.2.2. Absolute $ Opportunity Analysis
5. Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Vaccine
5.1. Introduction / Key Findings
5.2. Historical Market Size Value (US$ Million) & Volume (Units) Analysis By Vaccine, 2018 to 2022
5.3. Current and Future Market Size Value (US$ Million) & Volume (Units) Analysis and Forecast By Vaccine, 2023 to 2033
5.3.1. Attenuated Live Vaccines
5.3.2. Inactivated Vaccines
5.3.3. Toxoid Vaccines
5.3.4. DNA Vaccines
5.3.5. Recombinant Vaccines
5.3.6. Others
5.4. Y-o-Y Growth Trend Analysis By Vaccine, 2018 to 2022
5.5. Absolute $ Opportunity Analysis By Vaccine, 2023 to 2033
6. Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Animal
6.1. Introduction / Key Findings
6.2. Historical Market Size Value (US$ Million) & Volume (Units) Analysis By Animal, 2018 to 2022
6.3. Current and Future Market Size Value (US$ Million) & Volume (Units) Analysis and Forecast By Animal, 2023 to 2033
6.3.1. Companion Animals
6.3.1.1. Canine
6.3.1.2. Avian
6.3.1.3. Feline
6.3.2. Livestock Animals
6.3.2.1. Aquatic
6.3.2.2. Bovine
6.3.2.3. Porcine
6.3.2.4. Small Ruminant
6.3.2.5. Poultry
6.3.3. Equine
6.4. Y-o-Y Growth Trend Analysis By Animal, 2018 to 2022
6.5. Absolute $ Opportunity Analysis By Animal, 2023 to 2033
7. Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Disease Indication
7.1. Introduction / Key Findings
7.2. Historical Market Size Value (US$ Million) & Volume (Units) Analysis By Disease Indication, 2018 to 2022
7.3. Current and Future Market Size Value (US$ Million) & Volume (Units) Analysis and Forecast By Disease Indication, 2023 to 2033
7.3.1. Foot and Mouth Disease
7.3.2. Newcastle Disease
7.3.3. PPRS
7.3.4. Canine Parvovirus
7.3.5. Brucellosis
7.3.6. Avian Influenza
7.3.7. Others
7.4. Y-o-Y Growth Trend Analysis By Disease Indication, 2018 to 2022
7.5. Absolute $ Opportunity Analysis By Disease Indication, 2023 to 2033
8. Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By End-User
8.1. Introduction / Key Findings
8.2. Historical Market Size Value (US$ Million) & Volume (Units) Analysis By End-User, 2018 to 2022
8.3. Current and Future Market Size Value (US$ Million) & Volume (Units) Analysis and Forecast By End-User, 2023 to 2033
8.3.1. Hospital Pharmacies
8.3.2. Veterinary Clinics
8.3.3. Private Veterinary Pharmacies
8.3.4. Others
8.4. Y-o-Y Growth Trend Analysis By End-User, 2018 to 2022
8.5. Absolute $ Opportunity Analysis By End-User, 2023 to 2033
9. Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
9.1. Introduction
9.2. Historical Market Size Value (US$ Million) & Volume (Units) Analysis By Region, 2018 to 2022
9.3. Current Market Size Value (US$ Million) & Volume (Units) Analysis and Forecast By Region, 2023 to 2033
9.3.1. UAE
9.3.2. KSA
9.3.3. Turkey
9.3.4. Jordan
9.3.5. Sudan
9.3.6. Egypt
9.3.7. Rest of Middle East
9.4. Market Attractiveness Analysis By Region
10. UAE Market Analysis 2018 to 2022 and Forecast 2023 to 2033
10.1. Historical Market Size Value (US$ Million) & Volume (Units) Trend Analysis By Market Taxonomy, 2018 to 2022
10.2. Market Size Value (US$ Million) & Volume (Units) Forecast By Market Taxonomy, 2023 to 2033
10.2.1. By Country
10.2.2. By Vaccine
10.2.3. By Animal
10.2.4. By Disease Indication
10.2.5. By End-User
10.3. Market Attractiveness Analysis
10.3.1. By Country
10.3.2. By Vaccine
10.3.3. By Animal
10.3.4. By Disease Indication
10.3.5. By End-User
10.4. Key Takeaways
11. KSA Market Analysis 2018 to 2022 and Forecast 2023 to 2033
11.1. Historical Market Size Value (US$ Million) & Volume (Units) Trend Analysis By Market Taxonomy, 2018 to 2022
11.2. Market Size Value (US$ Million) & Volume (Units) Forecast By Market Taxonomy, 2023 to 2033
11.2.1. By Country
11.2.2. By Vaccine
11.2.3. By Animal
11.2.4. By Disease Indication
11.2.5. By End-User
11.3. Market Attractiveness Analysis
11.3.1. By Country
11.3.2. By Vaccine
11.3.3. By Animal
11.3.4. By Disease Indication
11.3.5. By End-User
11.4. Key Takeaways
12. Turkey Market Analysis 2018 to 2022 and Forecast 2023 to 2033
12.1. Historical Market Size Value (US$ Million) & Volume (Units) Trend Analysis By Market Taxonomy, 2018 to 2022
12.2. Market Size Value (US$ Million) & Volume (Units) Forecast By Market Taxonomy, 2023 to 2033
12.2.1. By Country
12.2.2. By Vaccine
12.2.3. By Animal
12.2.4. By Disease Indication
12.2.5. By End-User
12.3. Market Attractiveness Analysis
12.3.1. By Country
12.3.2. By Vaccine
12.3.3. By Animal
12.3.4. By Disease Indication
12.3.5. By End-User
12.4. Key Takeaways
13. Jordan Market Analysis 2018 to 2022 and Forecast 2023 to 2033
13.1. Historical Market Size Value (US$ Million) & Volume (Units) Trend Analysis By Market Taxonomy, 2018 to 2022
13.2. Market Size Value (US$ Million) & Volume (Units) Forecast By Market Taxonomy, 2023 to 2033
13.2.1. By Country
13.2.2. By Vaccine
13.2.3. By Animal
13.2.4. By Disease Indication
13.2.5. By End-User
13.3. Market Attractiveness Analysis
13.3.1. By Country
13.3.2. By Vaccine
13.3.3. By Animal
13.3.4. By Disease Indication
13.3.5. By End-User
13.4. Key Takeaways
14. Sudan Market Analysis 2018 to 2022 and Forecast 2023 to 2033
14.1. Historical Market Size Value (US$ Million) & Volume (Units) Trend Analysis By Market Taxonomy, 2018 to 2022
14.2. Market Size Value (US$ Million) & Volume (Units) Forecast By Market Taxonomy, 2023 to 2033
14.2.1. By Country
14.2.2. By Vaccine
14.2.3. By Animal
14.2.4. By Disease Indication
14.2.5. By End-User
14.3. Market Attractiveness Analysis
14.3.1. By Country
14.3.2. By Vaccine
14.3.3. By Animal
14.3.4. By Disease Indication
14.3.5. By End-User
14.4. Key Takeaways
15. Egypt Market Analysis 2018 to 2022 and Forecast 2023 to 2033
15.1. Historical Market Size Value (US$ Million) & Volume (Units) Trend Analysis By Market Taxonomy, 2018 to 2022
15.2. Market Size Value (US$ Million) & Volume (Units) Forecast By Market Taxonomy, 2023 to 2033
15.2.1. By Country
15.2.2. By Vaccine
15.2.3. By Animal
15.2.4. By Disease Indication
15.2.5. By End-User
15.3. Market Attractiveness Analysis
15.3.1. By Country
15.3.2. By Vaccine
15.3.3. By Animal
15.3.4. By Disease Indication
15.3.5. By End-User
15.4. Key Takeaways
16. Rest of Market Analysis 2018 to 2022 and Forecast 2023 to 2033
16.1. Historical Market Size Value (US$ Million) & Volume (Units) Trend Analysis By Market Taxonomy, 2018 to 2022
16.2. Market Size Value (US$ Million) & Volume (Units) Forecast By Market Taxonomy, 2023 to 2033
16.2.1. By Country
16.2.2. By Vaccine
16.2.3. By Animal
16.2.4. By Disease Indication
16.2.5. By End-User
16.3. Market Attractiveness Analysis
16.3.1. By Country
16.3.2. By Vaccine
16.3.3. By Animal
16.3.4. By Disease Indication
16.3.5. By End-User
16.4. Key Takeaways
17. Market Structure Analysis
17.1. Competition Dashboard
17.2. Competition Benchmarking
17.3. Market Share Analysis of Top Players
17.3.1. By Regional
17.3.2. By Vaccine
17.3.3. By Animal
17.3.4. By Disease Indication
17.3.5. By End-User
18. Competition Analysis
18.1. Competition Deep Dive
18.1.1. JOVAC
18.1.1.1. Overview
18.1.1.2. Product Portfolio
18.1.1.3. Profitability by Market Segments
18.1.1.4. Sales Footprint
18.1.1.5. Strategy Overview
18.1.1.5.1. Marketing Strategy
18.1.1.5.2. Product Strategy
18.1.1.5.3. Channel Strategy
18.1.2. Bioveta, Inc.
18.1.2.1. Overview
18.1.2.2. Product Portfolio
18.1.2.3. Profitability by Market Segments
18.1.2.4. Sales Footprint
18.1.2.5. Strategy Overview
18.1.2.5.1. Marketing Strategy
18.1.2.5.2. Product Strategy
18.1.2.5.3. Channel Strategy
18.1.3. Intervac Pvt. Ltd.
18.1.3.1. Overview
18.1.3.2. Product Portfolio
18.1.3.3. Profitability by Market Segments
18.1.3.4. Sales Footprint
18.1.3.5. Strategy Overview
18.1.3.5.1. Marketing Strategy
18.1.3.5.2. Product Strategy
18.1.3.5.3. Channel Strategy
18.1.4. Zoetis
18.1.4.1. Overview
18.1.4.2. Product Portfolio
18.1.4.3. Profitability by Market Segments
18.1.4.4. Sales Footprint
18.1.4.5. Strategy Overview
18.1.4.5.1. Marketing Strategy
18.1.4.5.2. Product Strategy
18.1.4.5.3. Channel Strategy
18.1.5. Elanco
18.1.5.1. Overview
18.1.5.2. Product Portfolio
18.1.5.3. Profitability by Market Segments
18.1.5.4. Sales Footprint
18.1.5.5. Strategy Overview
18.1.5.5.1. Marketing Strategy
18.1.5.5.2. Product Strategy
18.1.5.5.3. Channel Strategy
18.1.6. Merial
18.1.6.1. Overview
18.1.6.2. Product Portfolio
18.1.6.3. Profitability by Market Segments
18.1.6.4. Sales Footprint
18.1.6.5. Strategy Overview
18.1.6.5.1. Marketing Strategy
18.1.6.5.2. Product Strategy
18.1.6.5.3. Channel Strategy
18.1.7. Merck & Co. Inc.
18.1.7.1. Overview
18.1.7.2. Product Portfolio
18.1.7.3. Profitability by Market Segments
18.1.7.4. Sales Footprint
18.1.7.5. Strategy Overview
18.1.7.5.1. Marketing Strategy
18.1.7.5.2. Product Strategy
18.1.7.5.3. Channel Strategy
18.1.8. Bayer Pharma AG
18.1.8.1. Overview
18.1.8.2. Product Portfolio
18.1.8.3. Profitability by Market Segments
18.1.8.4. Sales Footprint
18.1.8.5. Strategy Overview
18.1.8.5.1. Marketing Strategy
18.1.8.5.2. Product Strategy
18.1.8.5.3. Channel Strategy
18.1.9. Ceva
18.1.9.1. Overview
18.1.9.2. Product Portfolio
18.1.9.3. Profitability by Market Segments
18.1.9.4. Sales Footprint
18.1.9.5. Strategy Overview
18.1.9.5.1. Marketing Strategy
18.1.9.5.2. Product Strategy
18.1.9.5.3. Channel Strategy
18.1.10. Boehringer Ingelheim
18.1.10.1. Overview
18.1.10.2. Product Portfolio
18.1.10.3. Profitability by Market Segments
18.1.10.4. Sales Footprint
18.1.10.5. Strategy Overview
18.1.10.5.1. Marketing Strategy
18.1.10.5.2. Product Strategy
18.1.10.5.3. Channel Strategy
19. Assumptions & Acronyms Used20. Research Methodology
